Global H1N1 Vaccines Market to Reach $3.2 Billion by 2030
The global market for H1N1 Vaccines estimated at US$2.2 Billion in the year 2022, is projected to reach a revised size of US$3.2 Billion by 2030, growing at a CAGR of 4.8% over the analysis period 2022-2030. Intramuscular, one of the segments analyzed in the report, is projected to record 6.2% CAGR and reach US$1.1 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Intranasal segment is readjusted to a revised 5% CAGR for the next 8-year period.The U.S. Market is Estimated at $588.1 Million, While China is Forecast to Grow at 8.7% CAGR
The H1N1 Vaccines market in the U.S. is estimated at US$588.1 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$734.5 Million by the year 2030 trailing a CAGR of 8.7% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1.9% and 3.5% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 2.9% CAGR.Select Competitors (Total 33 Featured) -
- Abbott Laboratories, Inc.
- Baxter International, Inc.
- Cipla Ltd.
- GlaxoSmithKline PLC
- Hualan Biological Engineering, Inc.
- Merck & Co., Inc.
- Mitsubishi Tanabe Pharma Corporation
- Pfizer, Inc.
- Sanofi
- Sinovac Biotech Ltd.
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIII. MARKET ANALYSISIV. COMPETITION
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- H1N1 Vaccines - Global Key Competitors Percentage Market Share in 2022 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
- Impact of Covid-19 and a Looming Global Recession
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World Recent Past, Current & Future Analysis for H1N1 Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 2: World 8-Year Perspective for H1N1 Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2023 & 2030
- Table 3: World Recent Past, Current & Future Analysis for Intramuscular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 4: World 8-Year Perspective for Intramuscular by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
- Table 5: World Recent Past, Current & Future Analysis for Intranasal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 6: World 8-Year Perspective for Intranasal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
- Table 7: World Recent Past, Current & Future Analysis for Conjugate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 8: World 8-Year Perspective for Conjugate by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
- Table 9: World Recent Past, Current & Future Analysis for Attenuated Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 10: World 8-Year Perspective for Attenuated Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
- Table 11: World Recent Past, Current & Future Analysis for Inactivated Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 12: World 8-Year Perspective for Inactivated Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
- Table 13: World Recent Past, Current & Future Analysis for Toxoid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 14: World 8-Year Perspective for Toxoid by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
- Table 15: World Recent Past, Current & Future Analysis for Other Vaccine Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 16: World 8-Year Perspective for Other Vaccine Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
- Table 17: World H1N1 Vaccines Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
UNITED STATES
- H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
- Table 18: USA Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 19: USA 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
CANADA
- Table 20: Canada Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 21: Canada 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
JAPAN
- H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
- Table 22: Japan Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 23: Japan 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
CHINA
- H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
- Table 24: China Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 25: China 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
EUROPE
- H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
- Table 26: Europe Recent Past, Current & Future Analysis for H1N1 Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 27: Europe 8-Year Perspective for H1N1 Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2023 & 2030
- Table 28: Europe Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 29: Europe 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
FRANCE
- H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
- Table 30: France Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 31: France 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
GERMANY
- H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
- Table 32: Germany Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 33: Germany 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
ITALY
- Table 34: Italy Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 35: Italy 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
UNITED KINGDOM
- H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
- Table 36: UK Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 37: UK 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
SPAIN
- Table 38: Spain Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 39: Spain 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
RUSSIA
- Table 40: Russia Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 41: Russia 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
REST OF EUROPE
- Table 42: Rest of Europe Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 43: Rest of Europe 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
ASIA-PACIFIC
- H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
- Table 44: Asia-Pacific Recent Past, Current & Future Analysis for H1N1 Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 45: Asia-Pacific 8-Year Perspective for H1N1 Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2023 & 2030
- Table 46: Asia-Pacific Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 47: Asia-Pacific 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
AUSTRALIA
- H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
- Table 48: Australia Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 49: Australia 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
INDIA
- H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
- Table 50: India Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 51: India 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
SOUTH KOREA
- Table 52: South Korea Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 53: South Korea 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
REST OF ASIA-PACIFIC
- Table 54: Rest of Asia-Pacific Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 55: Rest of Asia-Pacific 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
LATIN AMERICA
- H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
- Table 56: Latin America Recent Past, Current & Future Analysis for H1N1 Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 57: Latin America 8-Year Perspective for H1N1 Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2023 & 2030
- Table 58: Latin America Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 59: Latin America 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
ARGENTINA
- Table 60: Argentina Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 61: Argentina 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
BRAZIL
- Table 62: Brazil Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 63: Brazil 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
MEXICO
- Table 64: Mexico Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 65: Mexico 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
REST OF LATIN AMERICA
- Table 66: Rest of Latin America Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 67: Rest of Latin America 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
MIDDLE EAST
- H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
- Table 68: Middle East Recent Past, Current & Future Analysis for H1N1 Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 69: Middle East 8-Year Perspective for H1N1 Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2023 & 2030
- Table 70: Middle East Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 71: Middle East 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
IRAN
- Table 72: Iran Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 73: Iran 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
ISRAEL
- Table 74: Israel Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 75: Israel 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
SAUDI ARABIA
- Table 76: Saudi Arabia Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 77: Saudi Arabia 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
UNITED ARAB EMIRATES
- Table 78: UAE Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 79: UAE 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
REST OF MIDDLE EAST
- Table 80: Rest of Middle East Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 81: Rest of Middle East 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
AFRICA
- H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
- Table 82: Africa Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 83: Africa 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories, Inc.
- Baxter International, Inc.
- Cipla Ltd.
- GlaxoSmithKline PLC
- Hualan Biological Engineering, Inc.
- Merck & Co., Inc.
- Mitsubishi Tanabe Pharma Corporation
- Pfizer, Inc.
- Sanofi
- Sinovac Biotech Ltd.
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 268 |
Published | April 2024 |
Forecast Period | 2020 - 2027 |
Estimated Market Value ( USD | $ 1.9 Billion |
Forecasted Market Value ( USD | $ 2.7 Billion |
Compound Annual Growth Rate | 5.1% |
Regions Covered | Global |